CAMBRIDGE, Mass., Oct. 8,
2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a
biotechnology company developing targeted and immuno-oncology
therapeutics, today announced that data from the study of DKN-01 in
combination with KEYTRUDA® (pembrolizumab) in patients with
advanced gastroesophageal cancer will be presented in a poster
presentation at the European Society of Medical Oncology (ESMO)
2018 Annual Congress, taking place October 19-23, 2018 in Munich, Germany. The abstract was published
online in advance of the poster presentation that will include
additional patient data as the study has progressed since abstract
submission.
About the DKN-01 P102 clinical trial:
The P102 esophagogastric cancer study is a multipart study
evaluating DKN-01 as a monotherapy and in combination with
paclitaxel or pembrolizumab in patients with advanced relapsed or
refractory esophagogastric cancer. The arm evaluating DKN-01 with
pembrolizumab includes both dose escalation and dose confirmation
cohorts and is designed to evaluate the safety, pharmacokinetics
and efficacy of the combination. Patients will receive DKN-01 (150
mg or 300 mg on Days 1 & 15) plus pembrolizumab (200 mg on Day
1) of each 21-day cycle. The dose expansion cohort (n=55) includes
patients that are naïve (n=40) or refractory (n=15) to PD-1/PD-L1
antagonists.
Leap Poster Presentation
Details
Presentation Number: 660P
Title: Safety and Efficacy of a DKK1
Inhibitor (DKN-01) in Combination with Pembrolizumab (P) in
Patients (Pts) with Advanced Gastroesophageal (GE) Malignancies
Session Title: Gastrointestinal tumours – colorectal &
non-colorectal
Date: October 21, 2018
Time: 12:45pm – 1:45pm CEST
Location: Hall A3 - Poster Area Networking Hub, ICM München
About Leap Therapeutics
Leap Therapeutics
(NASDAQ:LPTX) is focused on developing targeted and immuno-oncology
therapeutics. Leap's most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01
is in clinical trials in patients with esophagogastric cancer,
biliary tract cancer, and gynecologic cancers, with an emerging
focus on patients with defined mutations of the Wnt pathway and in
combination with immune checkpoint inhibitors. Leap's second
clinical candidate, TRX518, is a humanized GITR agonist monoclonal
antibody designed to enhance the immune system's anti-tumor
response that is in two advanced solid tumor studies. For more
information about Leap Therapeutics, visit http://www.leaptx.com or
our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements relating to
Leap's expectations with respect to the development and advancement
of DKN-01, TRX518, and other programs, including the initiation,
timing and design of future studies, enrollment in future studies,
business development, and other future expectations, plans and
prospects. Leap has attempted to identify forward looking
statements by such terminology as ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Although Leap believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from our expectations. These risks and
uncertainties include, but are not limited to: the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for financing; the ability to complete a financing or
form business development relationships to fund our expenses; the
outcome, cost, and timing of our product development activities and
clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective
design or generate positive results; our ability to obtain and
maintain regulatory approval of our drug product candidates; our
plans to research, develop, and commercialize our drug product
candidates; our ability to achieve market acceptance of our drug
product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth
potential of the markets for our drug product candidates; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially will be included in Leap Therapeutics'
periodic filings with the Securities and Exchange
Commission (the "SEC"), including Leap Therapeutics' Form 10-K
that Leap filed with the SEC on February
23, 2018. These statements are only predictions and
involve known and unknown risks, uncertainties, and other factors.
Any forward looking statements contained in this release speak only
as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Heather Savelle or Mary Jenkins
212-600-1902
heather@argotpartners.com
mary@argopartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-data-from-study-evaluating-dkn-01-in-combination-with-keytruda-pembrolizumab-at-the-european-society-of-medical-oncology-2018-congress-300727298.html
SOURCE Leap Therapeutics, Inc.